Determination of the HCV protease inhibitor telaprevir in plasma and dried blood spot by liquid chromatography-tandem mass spectrometry

Therapeutic Drug Monitoring

Volumn 37, Issue 5, 2015, Pages 626-633

  Verweij Van Wissen, Corrien P W G M ^a   De Graaff Teulen, Marga J A ^a   De Kanter, Clara T M M ^a   Aarnoutse, Rob E ^a   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dried blood spot; Liquid chromatography tandem mass spectrometry; Plasma; Telaprevir

Indexed keywords

CITRIC ACID; FORMIC ACID; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; OLIGOPEPTIDE;

ACCURACY; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; DRIED BLOOD SPOT TESTING; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG STABILITY; EX VIVO STUDY; HEMATOCRIT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IONIZATION; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; BLOOD; BLOOD VOLUME; HEPATITIS C, CHRONIC; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROCEDURES;

ANTIVIRAL AGENTS; BLOOD VOLUME; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRIED BLOOD SPOT TESTING; DRUG STABILITY; HEMATOCRIT; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; TANDEM MASS SPECTROMETRY;

EID: 84941898542     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000189     Document Type: Article

References (11)

1. EMA. Incivo: summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002313/WC500115529.pdf. Accessed December 5, 2014.
2. FDA. Incivek: prescribing information. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed December 5, 2014.
3. Chakilam A, Chavan A, Smith G, et al. A validated HPLC-MS/MS assay method for determination of telaprevir and its R-diastereomer in human plasma. Sixth International Workshop on Clinical Pharmacology of Hepatitis Therapy, Cambridge, MA, June 22-23, 2011. Abstract PK-10.
4. Farnik H, El-Duweik J, Welsch C, et al. Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:4001-4006.
5. D'Avolio A, De Nicolo A, Agnesod D, et al. A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir. J Pharm Biomed Anal. 2013;78-79:217-223.
6. Aouri M, Moradpour D, Cavassini M, et al. Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir. Antimicrob Agents Chemother. 2013;57:3147-3158.
7. Liu G, Ji QC, Jemal M, et al. Approach to evaluating dried blood spot sample stability during drying process and discovery of a treated card to maintain analyte stability by rapid on-card pH modification. Anal Chem. 2011;83:9033-9038.
8. Bowen CL, Hemberger MD, Kehler JR, et al. Utility of dried blood spot sampling and storage for increased stability of photosensitive compounds. Bioanalysis. 2010;2:1823-1828.
9. D'Arienzo CJ, Ji QC, Discenza L, et al. DBS sampling can be used to stabilize prodrugs in drug discovery rodent studies without the addition of esterase inhibitors. Bioanalysis. 2010;2:1415-1422.
10. EMA. Guideline on Bioanalytical Method Validation. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf. Accessed December 5, 2014.
11. FDA. Guidance for Industry: Bioanalytical Method Validation. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070107. pdf. Accessed December 5, 2014.